Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relma-cel Followed by Tislelizumab for R/R CNS Large B-Cell Lymphoma
NCT06876688Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relmacabtagene autoleucel and tislelizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate at 3 months. Started Nov 2023; status: recruiting.
02
Drugs
relmacabtagene autoleuceltislelizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06876688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876688.